CD22 and B-cell non-Hodgkin lymphoma: In a first-in-human dose-escalation phase I study, α-particle emitting 227Th-labeled anti-CD22 antibody (BAY 1862864) showed clinical safety and tolerability in patients with CD22-positive relapsed/refractory B-cell NHL [50].